Gallbladder Cancer - Pipeline Review, H2 2011

Description: Gallbladder Cancer - Pipeline Review, H2 2011

Summary


Note:- Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Gallbladder Cancer.
- A review of the Gallbladder Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Gallbladder Cancer pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Gallbladder Cancer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Gallbladder Cancer pipeline depth and focus of Gallbladder Cancer therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Contents:

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Gallbladder Cancer Overview
Therapeutics Development
An Overview of Pipeline Products for Gallbladder Cancer
Gallbladder Cancer Therapeutics under Development by Companies
Gallbladder Cancer Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Gallbladder Cancer Therapeutics - Products under Development by Companies
Gallbladder Cancer Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Gallbladder Cancer Therapeutics Development
AstraZeneca PLC
MannKind Corporation
Gallbladder Cancer - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
MKC1106-PP - Drug Profile
Tarceva - Drug Profile
Erlotinib + Gemox - Drug Profile
Oxaliplatin + Erlotinib + Gemcitabine + Radiation therapy - Drug Profile
Gemzar + Xeloda - Drug Profile
FOLFIRI - Drug Profile
Gemcitabine + Radiation Therapy - Drug Profile
Sorafenib Tosylate - Drug Profile
3-AP + Gemcitabine - Drug Profile
Capecitabine + Gemcitabine - Drug Profile
Lapatinib Ditosylate - Drug Profile
erlotinib hydrochloride + gemcitabine hydrochloride + oxaliplatin - Drug Profile
Lapatinib Ditosylate - Drug Profile
Carcinoembryonic Antigen RNA-Pulsed DC Cancer Vaccine - Drug Profile
DAVANAT + 5-Fluorouracil - Drug Profile
Dolastatin 10 - Drug Profile
Capecitabine + Gemcitabine Hydrochloride + Radiation Therapy - Drug Profile
Trastuzumab - Drug Profile
Sorafenib Tosylate + Erlotinib Hydrochloride - Drug Profile
Gemcitabine + Capecitabine - Drug Profile
Gemcitabine + Oxaliplatin + Sorafenib - Drug Profile
Zactima + Gemzar - Drug Profile
Capecitabine + Oxaliplatin + Bevacizumab + Radiation Therapy - Drug Profile
Gemcitabine + Cisplatin + Sorafenib - Drug Profile
Gemcitabine + Cisplatin - Drug Profile
Recombinant Fowlpox-CEA(6D)/TRICOM Vaccine + GM-CSF - Drug Profile
Recombinant Fowlpox-CEA(6D) + Sargramostim - Drug Profile
Cyclophosphamide + Fludarabine Phosphate + Anti-Thymocyte Globulin + Cyclosporine + Peripheral Blood Stem Cell Transplantation + Therapeutic Allogeneic Lymphocytes - Drug Profile
Avastin + Tarceva - Drug Profile
Gd-Tex + Radiation Therapy - Drug Profile
Gemcitabine + 5-Fluorouracil + Leucovorin - Drug Profile
Cyclophosphamide + Fludarabine + Cyclosporin + Anti-Thymocyte Globulin + Allogeneic Peripheral Stem Cell Transplantation + White Blood Cell Transfusion - Drug Profile
Eloxatin + Xeloda - Drug Profile
Pertuzumab + Erlotinib - Drug Profile
Gemcitabine + Docetaxel + 5-Fluorouracil + Radiation Therapy - Drug Profile
Filgrastim + Pegylated Liposomal Doxorubicin Hydrochloride - Drug Profile
Gemcitabine + Carboplatin - Drug Profile
TS-1 + Gemcitabine - Drug Profile
Capecitabine + Oxaliplatin - Drug Profile
GEMOX - Drug Profile
Gemcitabine + Cisplatin - Drug Profile
Gemcitabine + Alimta - Drug Profile
Gemcitabine + S-1 - Drug Profile
Gemcitabine + Cisplatin - Drug Profile
Gemcitabine + TS-1 - Drug Profile
Gemcitabine + Cisplatin - Drug Profile
Gemcitabine + Radiation Therapy - Drug Profile
Glivec - Drug Profile
Anti-Thymocyte Globulin + Therapeutic Allogeneic Lymphocytes + Cyclophosphamide + Cyclosporine + Fludarabine phosphate - Drug Profile
Gemcitabine + Capecitabine - Drug Profile
Porfimer - Drug Profile
Porfimer - Drug Profile
Gemcitabine Hydrochloride + Oxaliplatin - Drug Profile
Modified FOLFOX6 + Cediranib Maleate - Drug Profile
Docetaxel + Oxaliplatin - Drug Profile
Gemcitabine + S-1 - Drug Profile
Gemcitabine - Drug Profile
Gemcitabine + Oxaliplatin - Drug Profile
GEMOX - Drug Profile
Oxaliplatin + 5-Fluorouracil + Leucovorin - Drug Profile
Gemcitabine + Cisplatin + S-1 - Drug Profile
Gemcitabine + Cisplatin - Drug Profile
Gemox 85 - Drug Profile
Gallbladder Cancer Therapeutics – Drug Profile Updates
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Gallbladder Cancer, H2 2011
Products under Development for Gallbladder Cancer – Comparative Analysis, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Comparative Analysis by Late Stage Development, H2 2011
Comparative Analysis by Mid Clinical Stage Development, H2 2011
Comparative Analysis by Early Clinical Stage Development, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
AstraZeneca PLC, 2011
MannKind Corporation, 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Gallbladder Cancer Therapeutics – Drug Profile Updates

List of Figures
Number of Products under Development for Gallbladder Cancer, H2 2011
Products under Development for Gallbladder Cancer – Comparative Analysis, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Late Stage Products, H2 2011
Mid Clinical Stage Products, H2 2011
Early Clinical Stage Products, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products, H2 2011
Assessment by Route of Administration, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Assessment by Stage and Molecule Type, H2 2011

Ordering:
Order Online - http://www.researchandmarkets.com/reports/1881623/

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Gallbladder Cancer - Pipeline Review, H2 2011
Web Address: http://www.researchandmarkets.com/reports/1881623/
Office Code: SCD23GIU

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td>USD 500</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License:</td>
<td>USD 1000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td>USD 1500</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr □ Mrs □ Dr □ Miss □ Ms □ Prof □
First Name: __________________________________________ Last Name: __________________________________________
Email Address: * __________________________________________
Job Title: __________________________________________
Organisation: __________________________________________
Address: __________________________________________
City: __________________________________________
Postal / Zip Code: __________________________________________
Country: __________________________________________
Phone Number: __________________________________________
Fax Number: __________________________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World